Journal article
Current opinion on optimal systemic treatment for metastatic colorectal cancer: Outcome of the ACTG/AGITG expert meeting ECCO 2013
TJ Price, E Segelov, M Burge, DG Haller, NC Tebbutt, CS Karapetis, CJA Punt, N Pavlakis, D Arnold, P Gibbs, JD Shapiro
Expert Review of Anticancer Therapy | Published : 2014
Abstract
The treatment of metastatic colorectal cancer has evolved greatly in the last 15 years, involving combined chemotherapy protocols and, in more recent times, new biologic agents. Clinical benefit from the use of targeted therapy with bevacizumab, aflibercept, cetuximab, panitumumab and regorafenib in the treatment of metastatic colorectal cancer is now well established with median overall survival accepted as over 24 months, and with super selection for extended RAS patients higher again. The optimal timing of treatment options requires careful consideration of predictive biomarkers, and importantly the potential for interactions, to derive the maximal benefit. A group of colorectal subspecia..
View full abstractGrants
Funding Acknowledgements
The Australian authors have received honoraria and travel support to attend national and international meetings for colorectal cancer from Merck Serono, Amgen, Roche and Sanofi Aventis. Disclosures for the international faculty are as follows: Punt CJA, advisor for Roche, Merck, Amgen, Bayer, Sanofi, Nordic Pharma; Dirk Arnold Research Funding Roche; Daniel Haller Consultant/honoraria, Sanofi-Aventis, Amgen, Genentech; Research funding Roche. The group meeting that enabled the material for this review to be assembled was supported by an unrestricted educational grant from Roche provided to the 'Adelaide Colorectal Tumour Group', which facilitated the meeting. Roche did not participate in data compilation or in the writing or viewing the submitted review. The corresponding author has had full access to all the data, warrants that all information has been reviewed and accepted by all participants. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.